Literature DB >> 16621040

Antiviral drug resistance.

Douglas D Richman1.   

Abstract

Almost 30 years ago it was proposed that the selection for antiviral drug resistance should be used as an indicator of antiviral drug activity. In addition to discriminating between cellular toxicity and specific activity directed against a viral target, drug resistant mutants have been used to confirm the mechanism of action of antiviral drugs, to discover the functions of several viral proteins and to provide insights into viral evolution and fitness. Drug resistance has also become a standard component of both the preclinical and clinical drug development process. For HIV and increasingly for other viruses drug resistance testing has become standard-of-care in clinical practice. A few selected examples are provided to illustrate each of these points.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621040     DOI: 10.1016/j.antiviral.2006.03.004

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  33 in total

1.  Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Authors:  Dongning Wang; Charles B Hicks; Neela D Goswami; Emi Tafoya; Ruy M Ribeiro; Fangping Cai; Alan S Perelson; Feng Gao
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  [Diagnostics and differential diagnosis of acute retinal necrosis].

Authors:  U Pleyer; S Metzner; J Hofmann
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

3.  Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

Authors:  Janet Karpinski; Ilona Hauber; Jan Chemnitz; Carola Schäfer; Maciej Paszkowski-Rogacz; Deboyoti Chakraborty; Niklas Beschorner; Helga Hofmann-Sieber; Ulrike C Lange; Adam Grundhoff; Karl Hackmann; Evelin Schrock; Josephine Abi-Ghanem; M Teresa Pisabarro; Vineeth Surendranath; Axel Schambach; Christoph Lindner; Jan van Lunzen; Joachim Hauber; Frank Buchholz
Journal:  Nat Biotechnol       Date:  2016-02-22       Impact factor: 54.908

4.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

Review 5.  Indole - a promising pharmacophore in recent antiviral drug discovery.

Authors:  Atukuri Dorababu
Journal:  RSC Med Chem       Date:  2020-11-06

6.  Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.

Authors:  Hong-Wang Zhang; Mervi Detorio; Brian D Herman; Sarah Solomon; Leda Bassit; James H Nettles; Aleksandr Obikhod; Si-Jia Tao; John W Mellors; Nicolas Sluis-Cremer; Steven J Coats; Raymond F Schinazi
Journal:  Eur J Med Chem       Date:  2011-05-30       Impact factor: 6.514

7.  FGI-104: a broad-spectrum small molecule inhibitor of viral infection.

Authors:  Michael S Kinch; Abdul S Yunus; Calli Lear; Hanwen Mao; Hanson Chen; Zena Fesseha; Guangxiang Luo; Eric A Nelson; Limin Li; Zhuhui Huang; Michael Murray; William Y Ellis; Lisa Hensley; Jane Christopher-Hennings; Gene G Olinger; Michael Goldblatt
Journal:  Am J Transl Res       Date:  2009-01-05       Impact factor: 4.060

Review 8.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

9.  Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Authors:  Daniela Vendrame; Marion Sourisseau; Virginie Perrin; Olivier Schwartz; Fabrizio Mammano
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

Review 10.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.